Two-year carcinogenicity study of acrylamide in Wistar Han rats with in utero exposure

Experimental and Toxicologic Pathology

Volumn 67, Issue 2, 2015, Pages 189-195

  Maronpot, R R ^a   Thoolen, R J M M ^b   Hansen, B ^c  

^a EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

^b Global Pathology Support   (Netherlands)

^c LPT Lab of Pharmacology/Toxicology   (Germany)

Author keywords

Carcinogenicity; In utero exposure; Mammary fibroadenomas; Myopathy; Neuropathy; Thyroid follicular cell tumors

Indexed keywords

ACRYLAMIDE; POLLUTANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST FIBROADENOMA; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; GESTATION PERIOD; HISTOPATHOLOGY; MALE; MESOTHELIOMA; MORTALITY; NONHUMAN; RAT; TESTIS TUMOR; THYROID FOLLICULAR CARCINOMA; TUMOR VOLUME; TUNICA VAGINALIS; WISTAR HANNOVER RAT; ANIMAL; CARCINOGEN TESTING; CHEMICALLY INDUCED; DOSE RESPONSE; EXPERIMENTAL MAMMARY NEOPLASM; INBRED RAT STRAIN; ORAL DRUG ADMINISTRATION; PATHOLOGY; POLLUTANT; PREGNANCY; PRENATAL EXPOSURE; THYROID TUMOR; TOXICITY;

RATTUS;

ACRYLAMIDE; ADMINISTRATION, ORAL; ANIMALS; CARCINOGENICITY TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; FEMALE; MALE; MAMMARY NEOPLASMS, ANIMAL; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS, INBRED STRAINS; THYROID NEOPLASMS;

EID: 84940166780     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2014.11.009     Document Type: Article

References (44)

1. Alison R.H., Capen C.C., Prentice D.E. Neoplastic lesions of questionable significance to humans. Toxicol Pathol 1994, 22:179-186.
2. Allen B., Zeiger E., Lawrence G., Friedman M., Shipp A. Dose-response modeling of in vivo genotoxicity data for use in risk assessment: some approaches illustrated by an analysis of acrylamide. Regul Toxicol Pharmacol 2005, 41:6-27.
3. Beland F.A., Mellick P.W., Olson G.R., Mendoza M.C., Marques M.M., Doerge D.R. Carcinogenicity of acrylamide in B6C3F (1) mice and F344/N rats from a 2-year drinking water exposure. Food Chem Toxicol 2013, 51:149-159.
4. Ben-Jonathan N., LaPensee C.R., LaPensee E.W. What can we learn from rodents about prolactin in humans. Endocr Rev 2008, 29:1-41.
5. Bowyer J.F., Latendresse J.R., Delongchamp R.R., Muskhelishvili L., Warbritton A.R., Thomas M., et al. The effects of subchronic acrylamide exposure on gene expression, neurochemistry, hormones, and histopathology in the hypothalamus-pituitary-thyroid axis of male Fischer 344 rats. Toxicol Appl Pharmacol 2008, 230:208-215.
6. Burek J.D., Albee R.R., Beyer J.E., Bell T.J., Carreon R.M., Morden D.C., et al. Subchronic toxicity of acrylamide administered to rats in the drinking water followed by up to 144 days of recovery. J Environ Pathol Toxicol 1980, 4:157-182.
7. Capen C.C., Martin S.L. Mechanisms that lead to disease of the endocrine system in animals. Toxicol Pathol 1989, 17:234-249.
8. Capen C.C. Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol Pathol 1997, 25:39.
9. Damjanov I., Friedman M.A. Mesotheliomas of tunica vaginalis testis of Fischer 344 (F344) rats treated with acrylamide: a light and electron microscopy study. In vivo 1998, 12:495-502.
10. Edwards P.M., Parker V.H. A simple, sensitive, and objective method for early assessment of acrylamide neuropathy in rats. Toxicol Appl Pharmacol 1977, 40:589-591.
11. EPA Toxicological review of acrylamide. U.S. Environmental Protection Agency, report EPA/635/R-07/009F 2010, EPA, Washington, DC.
12. EPA Science Advisory Board Toxicological review of acrylamide. U.S. Environmental Protection Agency, report EPA/635/R-07/009F 2008, EPA Science Advisory Board, Washington, DC.
13. Erdreich L.S., Friedman M.A. Epidemiologic evidence for assessing the carcinogenicity of acrylamide. Regul Toxicol Pharmacol 2004, 39:150-157.
14. Friedman M. Chemistry, biochemistry, and safety of acrylamide. A review. J Agric Food Chem 2003, 51:4504-4526.
15. Friedman M. Biological effects of Maillard browning products that may affect acrylamide safety in food: biological effects of Maillard products. Adv Exp Med Biol 2005, 561:135-156.
16. Friedman M.A., Dulak L.H., Stedham M.A. A lifetime oncogenicity study in rats with acrylamide. Fundam Appl Toxicol 1995, 27:95-105.
17. Greaves P. Histopathology of preclinical toxicity studies interpretation and relevance in drug safety evaluation 2012, Academic Press, Amsterdam.
18. Hamdy S.M., Bakeer H.M., Eskander E.F., Sayed O.N. Effect of acrylamide on some hormones and endocrine tissues in male rats. Hum Exp Toxicol 2012, 31:483-491.
19. Hamlin M., Banas D. Adrenal gland. Pathology of the Fischer rat 1990, 501-518. Academic Press, San Diego. G.A. Boorman, M. Eustis, C. Montgomery, W. MacKenzie (Eds.).
20. Harleman J.H., Hargreaves A., Andersson H., Kirk S. A review of the incidence and coincidence of uterine and mammary tumors in Wistar and Sprague-Dawley rats based on the RITA database and the role of prolactin. Toxicol Pathol 2012, 40:926-930.
21. Harvey P.W. Prolactin-induced mammary tumorigenesis is not a rodent-specific response. Toxicol Pathol 2011, 39:1020-1022.
22. Hooks W., Groom C., Laurent M-C., Taylor I. Tumour data from Han Wistar rat dietary and oral gavage tumorigenicity studies, completed over the period of 1994-2006. Toxicol Lett 2008, 180:S68-S69.
23. JECFA Joint FAO/WHO Expert Committee on food additives 2005, 47. WHO/FAO, Rome.
24. Jiang L., Cao J., An Y., Geng C., Qu S., Jiang L., et al. Genotoxicity of acrylamide in human hepatoma G2 (HepG2) cells. Toxicol In Vitro 2007, 21:1486-1492.
25. Johnson K.A., Gorzinski S.J., Bodner K.M., Campell R.A., Wolf C.H., Friedman M.A., et al. Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol Appl Pharmacol 1986, 85:154-168.
26. Khan M.A., Davis C.A., Foley G.L., Friedman M.A., Hansen L.G. Changes in thyroid gland morphology after acute acrylamide exposure. Toxicol Sci 1999, 47:151-157.
27. Laast V.A., Larsen T., Allison N., Hoenerhoff M.J., Boorman G.A. Distinguishing cystic degeneration from other aging lesions in the adrenal cortex of Sprague-Dawley rats. Toxicol Pathol 2014, 42:823-829.
28. Lafferty J.S., Kamendulis L.M., Kaster J., Jiang J., Klaunig J.E. Subchronic acrylamide treatment induces a tissue-specific increase in DNA synthesis in the rat. Toxicol Lett 2004, 154:95-103.
29. Lipworth L., Sonderman J.S., Tarone R.E., McLaughlin J.K. Review of epidemiologic studies of dietary acrylamide intake and the risk of cancer. Eur J Cancer Prev 2012, 21:375-386.
30. Manjanatha M.G., Aidoo A., Shelton S.D., Bishop M.E., McDaniel L.P., Lyn-Cook L.E., et al. Genotoxicity of acrylamide and its metabolite glycidamide administered in drinking water to male and female Big Blue mice. Environ Mol Mutagen 2006, 47:6-17.
31. Maronpot R.R., Zeiger E., McConnell E.E., Kolenda-Roberts H., Wall H., Friedman M.A. Induction of tunica vaginalis mesotheliomas in rats by xenobiotics. Crit Rev Toxicol 2009, 39:512-537.
32. Mottram D.S., Wedzicha B.L., Dodson A.T. Acrylamide is formed in the Maillard reaction. Nature 2002, 419:448-449.
33. Neumann F. Early indicators for carcinogenesis in sex-hormone-sensitive organs. Mutat Res 1991, 248:341-356.
34. O'Shaughnessy D.J., Losos G.J. Comparison of central and peripheral nervous system lesions caused by high-dose short-term and low-dose subchronic acrylamide treatment in rats. Toxicol Pathol 1986, 14:389-394.
35. Poteracki J., Walsh K.M. Spontaneous neoplasms in control Wistar rats: a comparison of reviews. Toxicol Sci 1998, 45:1-8.
36. Rosol T., DeLellis R., Harvey P., Sutcliffe C. Endocrine system. Haschek and Rousseaux's handbook of toxicologic pathology 2013, 2392-2492. Elsevier, Amsterdam. W. Haschek, C. Rousseaux, M. Wallig, B. Bolon, R. Ochoa, B. Mahler (Eds.).
37. Rudmann D., Cardiff R., Chouinard L., Goodman D., Kuttler K., Marxfeld H., et al. Proliferative and nonproliferative lesions of the rat and mouse mammary, Zymbal's, preputial, and clitoral glands. Toxicol Pathol 2012, 40(Suppl):7S-39S.
38. Shipp A., Lawrence G., Gentry R., McDonald T., Bartow H., Bounds J., et al. Acrylamide review of toxicity data and dose-response analyses for cancer and noncancer effects. Crit Rev Toxicol 2006, 36:481-608.
39. Tucker M.J. Diseases of the Wistar rat 1997, Taylor & Francis, London; Bristol, PA.
40. Vesper H.W., Caudill S.P., Osterloh J.D., Meyers T., Scott D., Meyers G.L. Exposure of the U.S. population to acrylamide in the National Health and Nutrition Examination Survey 2003-2004. Environ Health Perspect 2010, 118:278-283.
41. Vesper H.W., Slimani N., Hallmans G., Tjonneland A., Agudo A., Benetou V., et al. Cross-sectional study on acrylamide hemoglobin adducts in subpopulations from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. J Agric Food Chem 2008, 56:6046-6053.
42. Wall H. Acrylamide a two-year drinking water chronic toxicity study in Fischer 344 rats. A histopathology review and pathology working group review of proliferative lesions involving the mesothelial lining cells of the tunica vaginalis of the testes in a two-year drinking water chronic toxicity study in Fischer 344 rats with acrylamide 2005, Experimental Pathology Laboratories, Inc., (750-001).
43. Yousef M.I., El-Demerdash F.M. Acrylamide-induced oxidative stress and biochemical perturbations in rats. Toxicology 2006, 219:133-141.
44. Zeiger E., Recio L., Fennell T.R., Haseman J.K., Snyder R.W., Friedman M. Investigation of the low-dose response in the in vivo induction of micronuclei and adducts by acrylamide. Toxicol Sci 2009, 107:247-257.